# Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

> **NCT04920370** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 97 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALXN1720 SC
- **DRUG:** ALXN1720 IV
- **DRUG:** rHuPH20
- **DRUG:** Placebo SC
- **DRUG:** Placebo IV

## Key facts

- **NCT ID:** NCT04920370
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-04
- **Primary completion:** 2021-11-16
- **Final completion:** 2021-11-16
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04920370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04920370, "Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04920370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*